GlassScriptPhysician profile
Nasir Jalil Awan
NPI 1831141894
$53,786.44
in general payments reported to CMS, 2019-2025
48 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,656 · 2020: $832 · 2021: $1,182 · 2022: $2,144 · 2023: $14K · 2024: $14K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Honoraria: $17K · Food and Beverage: $6,214 · Travel and Lodging: $3,690 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,200 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,118.50 |
| Honoraria | $16,650.00 |
| Food and Beverage | $6,213.74 |
| Travel and Lodging | $3,690.12 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,200.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $39,739.28 | 2022-2025 | Sunosi |
| Inspire Medical Systems, INC. | $2,875.33 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,711.71 | 2019-2025 | Xywav |
| Astrazeneca Pharmaceuticals LP | $1,130.87 | 2019-2023 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $921.88 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Harmony Biosciences LLC | $895.37 | 2022-2024 | Wakix |
| Genzyme Corporation | $694.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $573.37 | 2019-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.23 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $479.27 | 2019-2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $335.38 | 2019-2021 | |
| United Therapeutics Corporation | $326.49 | 2019-2023 | Tyvaso |
| Insmed, INC. | $325.06 | 2019-2023 | Arikayce |
| Philips North America LLC | $310.48 | 2019-2022 | |
| 3b Medical, INC. | $294.75 | 2025 | Luna |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasir Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.